Volume 16, Issue 1 (Spring 2019)                   Sci J Iran Blood Transfus Organ 2019, 16(1): 24-31 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Yazdani Z, Mousavi Z, Ghasemi mehr N, Fatemi A, Farsinezhad A, Hassan Shahi G. Evaluation of alternations in the expression of CCR5 chemokine receptor in acute myeloid leukemia patients with monocytic differentiation after chemotherapy. Sci J Iran Blood Transfus Organ 2019; 16 (1) :24-31
URL: http://bloodjournal.ir/article-1-1217-en.html
Evaluation of alternations in the expression of CCR5 chemokine receptor in acute myeloid leukemia patients with monocytic differentiation after chemotherapy
Z. Yazdani , Z. Mousavi , N. Ghasemi mehr , A. Fatemi , A.R. Farsinezhad , Gh.H. Hassan Shahi *
Keywords: Key words: Acute Myeloid Leukemia, Chemotherapy, Monocytes, Tumors
Full-Text [PDF 551 kb]   (1273 Downloads)     |   Abstract (HTML)  (4225 Views)
Full-Text:   (2360 Views)
   References:
  1. Kupsa T, Horacek JM, Jebavy L. The role of cytokines in acute myeloid leukemia: a systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156(4): 291-301.
  2. de Oliveira CE, Amarante MK, Perim Ade L, Ozawa PM, Hiroki C, Freire Vitiello GA, et al. Absence of Association between CCR5 rs333 Polymorphism and Childhood Acute Lymphoblastic Leukemia. Advances in hematology. 2014;2014:924030.
  3. Annels NE, Willemze AJ, van der Velden VH, Faaij CM, van Wering E, Sie-Go DM, et al. Possible link between unique chemokine and homing receptor expression at diagnosis and relapse location in a patient with childhood T-ALL. Blood. 2004;103(7):2806-8.
  4. Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS. Chemokines in tumor progression and metastasis. Oncotarget. 2013;4(12):2171-85.
  5. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends in molecular medicine. 2010;16(3):133-44.
  6. Wang SW, Liu SC, Sun HL, Huang TY, Chan CH, Yang CY, et al. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Carcinogenesis. 2015;36(1):104-14.
  7. Faaij CM, Willemze AJ, Revesz T, Balzarolo M, Tensen CP, Hoogeboom M, et al. Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatric blood & cancer. 2010;55(2):344-8.
  8. Wierda RJ, van den Elsen PJ. Genetic and Epigenetic Regulation of CCR5 Transcription. Biology. 2012;1(3):869-79.
  9. Schlecker, E. Stojanovic, A. Eisen, C. Quack, C. Falk,
C. S. Umansky, V. Cerwenka, A. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol. 2012; 189(12): 5602-11.
  1. Zi J, Yuan S, Qiao J, Zhao K, Xu L, Qi K, et al. Treatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells. American journal of cancer research. 2017;7(4):869-80.
  2. Ma Y, Adjemian S, Galluzzi L, Zitvogel L, Kroemer G. Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. Oncoimmunology. 2014;3(1):e27663.
  3. Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer. 2007;109(12):2392-404.
  4. Balkwill, F. R. The chemokine system and cancer. J Pathol. 2012; 226(2): 148-57.
  5. Ban Y, Mai J, Li X, Mitchell-Flack M, Zhang T, Zhang L, et al. Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity. Cancer research. 2017;77(11):2857-68.
  6. urger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113(13):3050-8.
  7. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, et al. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British journal of haematology. 2015;171(5):726-35.
 
 
 
 
 


 
 
 
 
Sci J Iran Blood Transfus Organ 2019; 16(1): 24-31
Original Article
 

 

Evaluation of alternations in the expression of CCR5
chemokine receptor in acute myeloid leukemia patients
with monocytic differentiation after chemotherapy
 
Yazdani Z.1, Mousavi Z.1,2, Ghasemi-Mehr N.1, Fatemi A.1, Farsinejad A.R.3, Hassan Shahi Gh.4
 
 
1Faculty of Allied Medical Sciences, Kerman University of Medical Sciences, Kerman, Iran
2Iranshahr University of Medical Sciences, Iranshahr, Iran
3Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Kerman University of Medical Sciences, Kerman, Iran
4Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
 
 
 
Abstract
Background and Objectives
Acute myeloid leukemia (AML) is a heterogeneous cancer that is caused by various pathologic mechanisms. Cancer cells change the chemokine system. CCR5 receptor has an indirect effect on cancer progression by controlling immune response against the tumor. This receptor can accelerate tumor growth and play a significant role in tumor metastasis, and it has been shown that CCR5 antagonists inhibit tumor growth. In this study, we decided to investigate the CCR5 receptor in AML patients after the first stage chemotherapy.
 
Materials and Methods
This case-control study was conducted in Kerman University of Medical Sciences during 2017-2018. Twenty five AML patients with monocytic differentiation post the first stage of chemotherapy (the fourth week after chemotherapy), after being examined for the peripheral blood smear and confirmed for the absence of blast cells, were evaluated by flow cytometry for the expression of the CCR5 receptor on the peripheral blood leukocytes population and were compared with healthy controls. The data were analyzed by independent T-Test and SPSS (version 22).
 
Results
The results of this study showed that the mean expression of CCR-5 in the patients group post-chemotherapy (1.04 ± 0.26) was similar with the healthy control group (1.04 ± 0.16).  Moreover, there was no meaningful difference between the two groups.
 
Conclusions 
Chemotherapy has caused the CCR5 receptor expression to be in its base state compared to the healthy control group. Other chemokine syndromes and their receptors could be examined to find out which role would play a significant role in the recurrence of patients.
 
Key words: Acute Myeloid Leukemia, Chemotherapy, Monocytes, Tumors
 
Received: 24 Jul  2018
Accepted:  8 Sep 2018
 
 

Correspondence: Hassan Shahi Gh.H., PhD of Hematology & Blood Banking. Molecular Medicine Research Center, Rafsanjan University of Medical Sciences.
P.O.Box: 7717933777, Rafsanjan, Iran. Tel: (+9834) 31315203 ; Fax: (+9834) 34280097
E-mail: ghassanshahi@gmail.com 
Type of Study: Research | Subject: Hematology
Published: 2019/04/8
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Scientific Journal of Iran Blood Transfus Organ

Designed & Developed by : Yektaweb